Literature DB >> 19358256

Audiometric, surgical, and genetic findings in 15 ears of patients with osteogenesis imperfecta.

Freya K R Swinnen1, Els M R De Leenheer, Paul J Coucke, Cor W R J Cremers, Ingeborg J M Dhooge.   

Abstract

OBJECTIVES/HYPOTHESIS: To provide data on the outcome of stapes surgery in patients with osteogenesis imperfecta (OI). The audiometric results of 15 ears (12 patients), in which a stapes operation was performed, are presented and compared with results from literature. STUDY
DESIGN: Retrospective study.
METHODS: In 12 patients with genetically confirmed OI, intraoperative findings and audiometric evaluations were recorded.
RESULTS: In all patients the genetic mutation was located in the COL1A1 gene. Surgical findings in OI may be particular like mobile, atrophic stapes crura combined with a fixation of the stapes footplate, which may be thickened, and a hypervascularized or thickened middle-ear mucosa. Outcome for hearing in 13 primary surgered ears was good because at short-term follow-up the air-bone gap was reduced in all cases. These results were maintained in the long-term, with exception of one ear, in which progression of the sensorineural component occurred shortly after the operation. Although initial success was noted in two ears with revision surgery, in the long term this was only maintained in one of them.
CONCLUSIONS: In general, stapes surgery is successful in resolving the conductive hearing loss in OI patients, even in the long term. Hearing loss in OI is mostly of the mixed type, and the sensorineural component is reported to be progressive. Stapedotomy, by improving the hearing level, may facilitate the rehabilitation with a hearing aid. Because the identified mutation could be located in the COL1A1 gene in all patients, conductive hearing loss in OI caused by stapes fixation is possibly linked to a mutation in this gene. Laryngoscope, 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358256     DOI: 10.1002/lary.20155

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Osteogenesis imperfecta and hearing loss: an analysis of patients attended at a benchmark treatment center in southern Brazil.

Authors:  Andressa Colares da Costa Otavio; Adriane Ribeiro Teixeira; Temis Maria Félix; Letícia Petersen Schimidt Rosito; Sady Selaimen da Costa
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-31       Impact factor: 2.503

2.  Identification of a novel COL1A1 frameshift mutation, c.700delG, in a Chinese osteogenesis imperfecta family.

Authors:  Xiran Wang; Yu Pei; Jingtao Dou; Juming Lu; Jian Li; Zhaohui Lv
Journal:  Genet Mol Biol       Date:  2014-03-17       Impact factor: 1.771

3.  Identification of a novel heterozygous mutation in exon 50 of the COL1A1 gene causing osteogenesis imperfecta.

Authors:  S A S Aftab; N Reddy; N L Owen; R Pollitt; A Harte; P G McTernan; G Tripathi; T M Barber
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-07-01

4.  High Heterogeneity of Temporal Bone CT Aspects in Osteogenesis Imperfecta Is Not Linked to Hearing Loss.

Authors:  Aïcha Ltaief-Boudrigua; Genevieve Lina-Granade; Eric Truy; Ruben Hermann; Guillaume Chevrel
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.241

5.  Treatments for hearing loss in osteogenesis imperfecta: a systematic review and meta-analysis on their efficacy.

Authors:  Maialen Ugarteburu; Luis Cardoso; Claus-Peter Richter; Alessandra Carriero
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

6.  Hearing loss in osteogenesis imperfecta: characteristics and treatment considerations.

Authors:  Joseph P Pillion; David Vernick; Jay Shapiro
Journal:  Genet Res Int       Date:  2011-12-14

7.  Osteogenesis Imperfecta: Search for Mutations in Patients from the Republic of Bashkortostan (Russia).

Authors:  Dina Nadyrshina; Aliya Zaripova; Anton Tyurin; Ildar Minniakhmetov; Ekaterina Zakharova; Rita Khusainova
Journal:  Genes (Basel)       Date:  2022-01-10       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.